ABBV Today - Aug 11: $8 Billion Debt Deal

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

ABBV Today - Aug 11: $8 Billion Debt Deal

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about AbbVie. So, how did it do? Well, it was a pretty chill day, barely moved, closing up just a smidge at 0.26%.

So, what’s the scoop? AbbVie just took on a whopping $8 billion in debt for its Apogee deal. Yeah, that one stung a bit for some folks. When you hear “debt,” it usually raises eyebrows, especially for dividend investors. People were wondering if this move might hurt their precious payouts down the line.

Now, here’s the thing. Some analysts are a bit worried about AbbVie’s earnings potential. Like, Erste Group Bank just lowered its EPS estimates for FY2027. That’s not exactly a warm hug for investors looking for growth. And to add to the mix, BNP Paribas adjusted their price target on AbbVie to $247, which is a bit of a bump up from where it was, but they’re still neutral on the stock. So, it’s like, they’re saying, “We see potential, but we’re not super excited about it.”

But don’t let that totally bring you down. AbbVie did post some strong Q2 earnings recently, which had some investors feeling a little more optimistic. It’s like they’re trying to balance the good with the not-so-good.

One thing worth knowing about is that this big debt deal might signal AbbVie’s plans to invest heavily in its pipeline. They’re all about growth, and sometimes you gotta take risks to get there. So, keep an eye on how they manage this debt and what it means for their future projects.

Alright, that’s the lowdown on AbbVie today! Remember, this is just for fun and info—no financial advice here. Catch you later!

まだレビューはありません